Short Interest in Genenta Science S.p.A. Unsponsored ADR (NASDAQ:GNTA) Decreases By 40.4%

Genenta Science S.p.A. Unsponsored ADR (NASDAQ:GNTA) was the target of a significant decline in short interest in December. As of December 15th, there was short interest totaling 100,401 shares, a decline of 40.4% from the November 30th total of 168,471 shares. Based on an average daily trading volume, of 91,627 shares, the days-to-cover ratio is presently 1.1 days. Currently, 0.7% of the company’s stock are sold short. Currently, 0.7% of the company’s stock are sold short. Based on an average daily trading volume, of 91,627 shares, the days-to-cover ratio is presently 1.1 days.

Genenta Science Trading Up 1.4%

Shares of NASDAQ GNTA traded up $0.02 during mid-day trading on Tuesday, reaching $1.42. The company had a trading volume of 155,112 shares, compared to its average volume of 187,363. Genenta Science has a twelve month low of $1.28 and a twelve month high of $10.00. The stock’s 50 day moving average is $2.12 and its 200-day moving average is $2.99.

Genenta Science (NASDAQ:GNTA) last issued its earnings results on Friday, October 10th. The company reported ($0.10) EPS for the quarter. As a group, sell-side analysts anticipate that Genenta Science will post -0.93 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Genenta Science

An institutional investor recently bought a new position in Genenta Science stock. Citadel Advisors LLC acquired a new stake in shares of Genenta Science S.p.A. Unsponsored ADR (NASDAQ:GNTA) during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 12,486 shares of the company’s stock, valued at approximately $41,000. Citadel Advisors LLC owned approximately 0.07% of Genenta Science as of its most recent filing with the Securities & Exchange Commission. 15.13% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Genenta Science in a research report on Monday. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock has a consensus rating of “Sell”.

Genenta Science Company Profile

Genenta Science (NASDAQ: GNTA) is a clinical-stage biotechnology company focused on the development of in vivo hematopoietic stem cell (HSC) gene therapies for the treatment of solid tumors. The company’s proprietary platform enables the transplantation of genetically engineered HSCs that home to tumor sites and continuously deliver immunomodulatory agents. By harnessing the patient’s own stem cells, Genenta aims to establish a sustained, localized anti-tumor immune response with the potential to overcome limitations of traditional cytokine or antibody therapies.

Genenta’s lead product candidate, Temferon, consists of autologous HSCs engineered to produce interferon-alpha under the control of a tumor microenvironment–activated promoter.